Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FLT-PET scan Clear all
Completed Phase 1 Interventional Results available

Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

NCT00694096
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Sunitinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer

NCT00572728
View directory record Official record
Conditions
Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
CT, 18F-FLT, PET
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
27
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional

18F-FLT PET Imaging in Patients With Advanced Melanoma

NCT02891616
View directory record Official record
Conditions
Melanoma
Interventions
fludeoxyglucose F 18, Positron emission tomography-computed tomography, 18F-fluorothymidine, Positron emission tomography-magnetic resonance imaging
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

NCT02819024
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Dexamethasone, Device for PET, Laboratory Biomarker Analysis, Positron Emission Tomography
Drug · Device · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Image-Guided Stereotactic Biopsy of High Grade Gliomas

NCT00979810
View directory record Official record
Conditions
Brain Cancer, Glioma
Interventions
18F-FLT PET Scan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 89 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 11, 2026, 2:08 PM EDT
Not listed Not applicable Interventional

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)

NCT01308905
View directory record Official record
Conditions
Neuroblastoma
Interventions
FLT-PET
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
1 Day to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Multi-Tracer PET Assessment of Primary Brain Tumors

NCT00813566
View directory record Official record
Conditions
Brain Tumors, Cancer
Interventions
[18F]fluoro-2-deoxy-D-glucose (FDG), 3'-deoxy-3'-[18F]fluorothymidine (FLT), [15O]-H2O, [11C]Acetate
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer

NCT01243619
View directory record Official record
Conditions
Esophageal Cancer
Interventions
3'-deoxy-3'-(18) F-fluorothymidine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Not applicable Interventional

FLT-PET Imaging for MDS

NCT01535456
View directory record Official record
Conditions
AML, MDS
Interventions
FLT-PET scans
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 11, 2026, 2:08 PM EDT
Recruiting Phase 1 Interventional

Pilot Imaging Study of Leukemia

NCT03633955
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Ambiguous Lineage Leukemia or Lymphoma, Myeloma
Interventions
FLT
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies

NCT00859118
View directory record Official record
Conditions
Neoplasms
Interventions
AG-013736
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00559897
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
3'-deoxy-3'-[18F]FLT, Single photon emission computed tomography
Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Sep 11, 2026, 2:08 PM EDT
Withdrawn No phase listed Observational

FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions

NCT02328300
View directory record Official record
Conditions
Brain Lesions, Brain Metastasis, Brain Metastases
Interventions
FLT PET/MR
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation

NCT00847509
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer
Interventions
[F-18]FLT
Drug
Lead sponsor
Siemens Molecular Imaging
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 11, 2026, 2:08 PM EDT
Completed No phase listed Observational

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

NCT01410630
View directory record Official record
Conditions
Lymphoma, Lymphoma, Non-Hodgkin, Large B Cell Diffuse Lymphoma
Interventions
FLT-PET/CT, FDG-PET/CT, FLT
Diagnostic Test · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Omaha, Nebraska • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 11, 2026, 2:08 PM EDT
Completed No phase listed Observational

Personalized Translational Platform for Biomarker Discovery in Brain Tumors

NCT01240161
View directory record Official record
Conditions
High Grade Glioma
Interventions
FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT
Drug
Lead sponsor
Marcelo F. Di Carli, MD, FACC
Other
Eligibility
18 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
San Diego, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

NCT01717391
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms, Prostatic Neoplasms
Interventions
fluorothymidine F 18
Drug
Lead sponsor
John M. Buatti
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

NCT00499135
View directory record Official record
Conditions
Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Sunitinib Malate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

NCT01143779
View directory record Official record
Conditions
Advanced Cancer
Interventions
FLT-PET
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Not applicable Interventional

Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx

NCT00767273
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PET Scan, FLT, FDG
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

NCT00708448
View directory record Official record
Conditions
Cancer, Non Small Cell Lung Cancer
Interventions
PET Imaging, Erlotinib, Bevacizumab
Radiation · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Not applicable Interventional Results available

PET/CT Evaluation of Treatment Response in Breast Cancer

NCT01222416
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiopharmaceutical Administration [18F]-FDG, Radiopharmaceutical: [18F]-FLT
Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Early Phase 1 Interventional

Evaluating Tumor Pseudoprogression With FLT-PET and MRI

NCT01105988
View directory record Official record
Conditions
Glioblastoma
Interventions
Radiologic exams
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

NCT03318497
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 11, 2026, 2:08 PM EDT